image
Healthcare - Medical - Devices - NYSE - US
$ 10.88
2.06 %
$ 911 M
Market Cap
-16.24
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one FNA stock under the worst case scenario is HIDDEN Compared to the current market price of 10.9 USD, Paragon 28, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one FNA stock under the base case scenario is HIDDEN Compared to the current market price of 10.9 USD, Paragon 28, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one FNA stock under the best case scenario is HIDDEN Compared to the current market price of 10.9 USD, Paragon 28, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
216 M REVENUE
19.30%
-45.7 M OPERATING INCOME
-30.30%
-57.5 M NET INCOME
14.54%
-63.9 M OPERATING CASH FLOW
-29.91%
-27 M INVESTING CASH FLOW
55.54%
129 M FINANCING CASH FLOW
225.81%
62.3 M REVENUE
2.16%
-8.45 M OPERATING INCOME
21.51%
-14.5 M NET INCOME
-5.23%
-2.65 M OPERATING CASH FLOW
74.08%
-3.84 M INVESTING CASH FLOW
-11.42%
133 K FINANCING CASH FLOW
-92.53%
Balance Sheet Paragon 28, Inc.
image
Current Assets 216 M
Cash & Short-Term Investments 75.6 M
Receivables 38.1 M
Other Current Assets 102 M
Non-Current Assets 125 M
Long-Term Investments 0
PP&E 74.1 M
Other Non-Current Assets 50.8 M
Current Liabilities 51.2 M
Accounts Payable 21.7 M
Short-Term Debt 1.18 M
Other Current Liabilities 28.4 M
Non-Current Liabilities 112 M
Long-Term Debt 111 M
Other Non-Current Liabilities 868 K
EFFICIENCY
Earnings Waterfall Paragon 28, Inc.
image
Revenue 216 M
Cost Of Revenue 52 M
Gross Profit 164 M
Operating Expenses 210 M
Operating Income -45.7 M
Other Expenses 11.9 M
Net Income -57.5 M
RATIOS
75.99% GROSS MARGIN
75.99%
-21.10% OPERATING MARGIN
-21.10%
-26.59% NET MARGIN
-26.59%
-32.37% ROE
-32.37%
-16.89% ROA
-16.89%
-15.90% ROIC
-15.90%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Paragon 28, Inc.
image
Net Income -57.5 M
Depreciation & Amortization 15.5 M
Capital Expenditures -28 M
Stock-Based Compensation 12.4 M
Change in Working Capital -53 M
Others -4.25 M
Free Cash Flow -91.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Paragon 28, Inc.
image
Wall Street analysts predict an average 1-year price target for FNA of $13 , with forecasts ranging from a low of $11 to a high of $15 .
FNA Lowest Price Target Wall Street Target
11 USD 1.10%
FNA Average Price Target Wall Street Target
13 USD 19.49%
FNA Highest Price Target Wall Street Target
15 USD 37.87%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Paragon 28, Inc.
image
Sold
0-3 MONTHS
5.18 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
255 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
1 month ago
Dec 06, 2024
Sell 257 K USD
MVM Partners, LLC
10 percent owner
- 25485
10.07 USD
1 month ago
Dec 09, 2024
Sell 145 K USD
MVM Partners, LLC
10 percent owner
- 14403
10.05 USD
1 month ago
Dec 06, 2024
Sell 22.6 K USD
WRIGHT KRISTINA
Director
- 2260
10 USD
1 month ago
Dec 06, 2024
Sell 1 K USD
WRIGHT KRISTINA
Director
- 100
10.02 USD
1 month ago
Dec 04, 2024
Sell 184 K USD
MVM Partners, LLC
10 percent owner
- 18109
10.14 USD
1 month ago
Dec 05, 2024
Sell 565 K USD
MVM Partners, LLC
10 percent owner
- 55818
10.13 USD
1 month ago
Nov 26, 2024
Sell 441 K USD
MVM Partners, LLC
10 percent owner
- 44014
10.03 USD
1 month ago
Nov 27, 2024
Sell 42.6 K USD
MVM Partners, LLC
10 percent owner
- 4256
10 USD
1 month ago
Nov 22, 2024
Sell 733 K USD
MVM Partners, LLC
10 percent owner
- 72133
10.16 USD
1 month ago
Nov 25, 2024
Sell 109 K USD
MVM Partners, LLC
10 percent owner
- 10835
10.09 USD
1 month ago
Nov 20, 2024
Sell 1.52 M USD
MVM Partners, LLC
10 percent owner
- 147581
10.28 USD
1 month ago
Nov 21, 2024
Sell 1.12 M USD
MVM Partners, LLC
10 percent owner
- 107366
10.41 USD
2 months ago
Nov 13, 2024
Sell 41.8 K USD
WRIGHT KRISTINA
Director
- 4181
10 USD
10 months ago
Mar 15, 2024
Bought 255 K USD
DaCosta Albert
See Remarks
+ 28000
9.1152 USD
1 year ago
Nov 10, 2023
Bought 260 K USD
DaCosta Albert
see remarks
+ 30500
8.51 USD
1 year ago
Jun 14, 2023
Sell 128 K USD
SCHNETTLER THOMAS P
Director
- 6900
18.5437 USD
2 years ago
Nov 25, 2022
Sell 254 K USD
Friedman Jonathan I
- 12500
20.3451 USD
2 years ago
Dec 01, 2022
Sell 51.2 K USD
Friedman Jonathan I
- 2500
20.5 USD
1 year ago
Jun 06, 2023
Sell 126 K USD
WRIGHT KRISTINA
Director
- 6800
18.5801 USD
1 year ago
Feb 17, 2023
Sell 3.44 M USD
Bird B. AG
10 percent owner
- 202500
17 USD
1 year ago
Feb 17, 2023
Sell 1.28 M USD
DaCosta Albert
See Remarks
- 75000
17 USD
1 year ago
Feb 17, 2023
Sell 1.28 M USD
DaCosta Albert
See Remarks
- 75000
17 USD
1 year ago
Jan 26, 2023
Sell 196 K USD
MVM Partners, LLC
10 percent owner
- 9597
20.4161 USD
1 year ago
Jan 30, 2023
Sell 23 M USD
Bird B. AG
10 percent owner
- 1350000
17 USD
1 year ago
Jan 30, 2023
Sell 8.5 M USD
DaCosta Albert
See Remarks
- 500000
17 USD
1 year ago
Jan 30, 2023
Sell 8.5 M USD
DaCosta Albert
See Remarks
- 500000
17 USD
2 years ago
Dec 23, 2022
Sell 735 K USD
Jarboe Matthew
Chief Commercial Officer
- 35110
20.9253 USD
2 years ago
Dec 21, 2022
Sell 521 K USD
Jarboe Matthew
Chief Commercial Officer
- 24913
20.9132 USD
2 years ago
Dec 19, 2022
Sell 196 K USD
MVM Partners LLP
Director
- 9597
20.4161 USD
2 years ago
Dec 13, 2022
Sell 30.6 K USD
MVM Partners LLP
Director
- 1510
20.2524 USD
2 years ago
Dec 14, 2022
Sell 218 K USD
MVM Partners LLP
Director
- 10668
20.4375 USD
2 years ago
Dec 08, 2022
Sell 582 K USD
MVM Partners LLP
Director
- 29000
20.0744 USD
2 years ago
Dec 08, 2022
Sell 268 K USD
MVM Partners LLP
Director
- 13273
20.2245 USD
2 years ago
Dec 09, 2022
Sell 37.9 K USD
MVM Partners LLP
Director
- 1873
20.2437 USD
2 years ago
Dec 01, 2022
Sell 585 K USD
DaCosta Albert
See Remarks
- 30000
19.5141 USD
2 years ago
Nov 30, 2022
Sell 117 K USD
MVM Partners LLP
Director
- 5829
20.1355 USD
2 years ago
Dec 01, 2022
Sell 20.1 K USD
MVM Partners LLP
Director
- 1000
20.1 USD
2 years ago
Dec 01, 2022
Sell 4.05 K USD
MVM Partners LLP
Director
- 200
20.23 USD
2 years ago
Nov 25, 2022
Sell 489 K USD
MVM Partners LLP
Director
- 24171
20.2306 USD
2 years ago
Nov 23, 2022
Sell 19.9 K USD
MVM Partners LLP
Director
- 987
20.13 USD
2 years ago
Nov 14, 2022
Sell 547 K USD
MVM Partners LLP
Director
- 27013
20.2601 USD
2 years ago
Nov 15, 2022
Sell 40.3 K USD
MVM Partners LLP
Director
- 2000
20.1672 USD
2 years ago
Nov 07, 2022
Sell 1.13 M USD
Rosenthal Lee
Director
- 61001
18.4824 USD
2 years ago
Oct 28, 2022
Sell 49 K USD
MVM Partners LLP
Director
- 2497
19.6423 USD
2 years ago
Oct 28, 2022
Sell 595 K USD
MVM Partners LLP
Director
- 30000
19.8228 USD
2 years ago
Oct 28, 2022
Sell 390 K USD
MVM Partners LLP
Director
- 20110
19.3723 USD
2 years ago
Oct 31, 2022
Sell 547 K USD
MVM Partners LLP
Director
- 27487
19.9075 USD
2 years ago
Aug 08, 2022
Sell 775 K USD
Rosenthal Lee
Director
- 39690
19.5341 USD
2 years ago
Aug 08, 2022
Sell 1.85 M USD
Rosenthal Lee
Director
- 95031
19.511 USD
2 years ago
Aug 10, 2022
Sell 3.02 M USD
Rosenthal Lee
Director
- 150609
20.0493 USD
2 years ago
Aug 10, 2022
Sell 2.37 M USD
Rosenthal Lee
Director
- 114775
20.6238 USD
2 years ago
Aug 11, 2022
Sell 1.02 M USD
Rosenthal Lee
Director
- 49498
20.6635 USD
2 years ago
Aug 11, 2022
Sell 253 K USD
Rosenthal Lee
Director
- 12030
21.0415 USD
2 years ago
Aug 15, 2022
Sell 1.31 M USD
Rosenthal Lee
Director
- 64519
20.3023 USD
2 years ago
Aug 16, 2022
Sell 52.6 K USD
Rosenthal Lee
Director
- 2615
20.1003 USD
2 years ago
Sep 12, 2022
Sell 489 K USD
Rosenthal Lee
Director
- 25674
19.0632 USD
2 years ago
Sep 14, 2022
Sell 111 K USD
Rosenthal Lee
Director
- 5836
19.0692 USD
2 years ago
Sep 15, 2022
Sell 42.1 K USD
Rosenthal Lee
Director
- 2200
19.1285 USD
2 years ago
Oct 04, 2022
Sell 82.6 K USD
Rosenthal Lee
Director
- 4328
19.0964 USD
2 years ago
Jul 20, 2022
Sell 798 K USD
Rosenthal Lee
Director
- 42865
18.6257 USD
2 years ago
Jul 21, 2022
Sell 1.08 M USD
Rosenthal Lee
Director
- 58171
18.4838 USD
2 years ago
Jul 21, 2022
Sell 514 K USD
Rosenthal Lee
Director
- 27838
18.4681 USD
2 years ago
Jul 25, 2022
Sell 386 K USD
Rosenthal Lee
Director
- 20813
18.5266 USD
2 years ago
Jul 25, 2022
Sell 690 K USD
Rosenthal Lee
Director
- 37292
18.5097 USD
2 years ago
Jul 27, 2022
Sell 896 K USD
Rosenthal Lee
Director
- 46113
19.4363 USD
2 years ago
Jul 28, 2022
Sell 1.95 K USD
Rosenthal Lee
Director
- 100
19.54 USD
2 years ago
Jul 28, 2022
Sell 96.7 K USD
Rosenthal Lee
Director
- 5080
19.0345 USD
2 years ago
Jul 29, 2022
Sell 24.5 K USD
Rosenthal Lee
Director
- 1290
19 USD
2 years ago
Aug 01, 2022
Sell 121 K USD
Rosenthal Lee
Director
- 6372
19.023 USD
2 years ago
Aug 03, 2022
Sell 1.42 M USD
Rosenthal Lee
Director
- 73408
19.3198 USD
2 years ago
Aug 04, 2022
Sell 781 K USD
Rosenthal Lee
Director
- 39937
19.5601 USD
2 years ago
Aug 05, 2022
Sell 2.34 M USD
Rosenthal Lee
Director
- 119466
19.5555 USD
2 years ago
Oct 26, 2022
Sell 176 K USD
MVM Partners LLP
Director
- 9156
19.1797 USD
2 years ago
Oct 27, 2022
Sell 14 K USD
MVM Partners LLP
Director
- 734
19.1376 USD
2 years ago
Oct 04, 2022
Sell 29 K USD
MVM Partners LLP
Director
- 1517
19.0936 USD
2 years ago
Sep 20, 2022
Sell 213 K USD
MVM Partners LLP
10 percent owner
- 11485
18.5202 USD
2 years ago
Sep 21, 2022
Sell 311 K USD
MVM Partners LLP
10 percent owner
- 16735
18.6015 USD
2 years ago
Sep 21, 2022
Sell 155 K USD
MVM Partners LLP
10 percent owner
- 8201
18.9277 USD
2 years ago
Sep 15, 2022
Sell 115 K USD
MVM Partners LLP
10 percent owner
- 6043
19.0461 USD
2 years ago
Sep 16, 2022
Sell 33 K USD
MVM Partners LLP
10 percent owner
- 1780
18.5396 USD
2 years ago
Sep 13, 2022
Sell 10.9 K USD
MVM Partners LLP
10 percent owner
- 575
18.9257 USD
2 years ago
Sep 14, 2022
Sell 269 K USD
MVM Partners LLP
10 percent owner
- 14101
19.079 USD
2 years ago
Sep 14, 2022
Sell 564 K USD
MVM Partners LLP
10 percent owner
- 30000
18.8117 USD
2 years ago
Sep 14, 2022
Sell 154 K USD
MVM Partners LLP
10 percent owner
- 8134
18.9235 USD
2 years ago
Sep 09, 2022
Sell 546 K USD
MVM Partners LLP
10 percent owner
- 29200
18.7139 USD
2 years ago
Sep 12, 2022
Sell 15.1 K USD
MVM Partners LLP
10 percent owner
- 800
18.8838 USD
2 years ago
Sep 12, 2022
Sell 975 K USD
MVM Partners LLP
10 percent owner
- 51231
19.0401 USD
2 years ago
Sep 08, 2022
Sell 540 K USD
DaCosta Albert
See Remarks
- 30000
18.0069 USD
2 years ago
Aug 26, 2022
Sell 15 K USD
MVM Partners LLP
director:
- 800
18.7775 USD
2 years ago
Aug 24, 2022
Sell 331 K USD
MVM Partners LLP
director:
- 17876
18.5388 USD
2 years ago
Aug 15, 2022
Sell 46 K USD
MVM Partners LLP
director:
- 2301
19.9704 USD
2 years ago
Aug 11, 2022
Sell 584 K USD
Jarboe Matthew
Chief Commercial Officer
- 27878
20.937 USD
2 years ago
Aug 10, 2022
Sell 709 K USD
MVM Partners LLP
director:
- 34099
20.7782 USD
2 years ago
Aug 08, 2022
Sell 357 K USD
MVM Partners LLP
director:
- 18303
19.4787 USD
2 years ago
Aug 04, 2022
Sell 475 K USD
MVM Partners LLP
director:
- 25000
18.9976 USD
2 years ago
Jul 14, 2022
Sell 260 K USD
Jarboe Matthew
Chief Commercial Officer
- 13679
19.0024 USD
2 years ago
Jul 08, 2022
Sell 1.24 M USD
Jarboe Matthew
Chief Commercial Officer
- 63889
19.4433 USD
2 years ago
Jun 06, 2022
Sell 115 K USD
Bono Frank S.
Chief Technology Officer
- 6322
18.1548 USD
2 years ago
May 27, 2022
Sell 435 K USD
Bono Frank S.
Chief Technology Officer
- 24155
17.99 USD
7. News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accesswire.com - 1 week ago
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accesswire.com - 1 week ago
FNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Paragon 28, Inc. and Encourages Investors to Contact the Firm NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accesswire.com - 1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Paragon 28, Inc. (FNA) And Encourages Stockholders to Connect NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accesswire.com - 2 weeks ago
Paragon 28 to Present at the 43rd Annual J.P. Morgan Healthcare Conference ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Chadi Chahine, CFO & EVP of Supply Chain Operations, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the in. businesswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Paragon 28, Inc. (FNA) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accesswire.com - 2 weeks ago
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESSWIRE / January 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accesswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Paragon 28, Inc. (FNA) Investors to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accesswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Paragon 28, Inc. (FNA) And Encourages Investors to Reach Out NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Paragon 28, Inc. ("Paragon 28" or "the Company") (NYSE:FNA). Investors who purchased Paragon 28 securities prior to May 5, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FNA. accesswire.com - 2 weeks ago
Paragon 28 Appoints Dave Demski to Board of Directors ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), (the “Company”) a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has. businesswire.com - 1 month ago
Wall Street Analysts Predict a 39.67% Upside in Paragon 28, Inc. (FNA): Here's What You Should Know The consensus price target hints at a 39.7% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 1 month ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Paragon 28, Inc.(FNA) Shareholders NEW YORK , Dec. 2, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Paragon 28, Inc. ("Paragon 28, Inc." or the "Company") (NYSE: FNA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Paragon 28, Inc. investors who were adversely affected by alleged securities fraud between May 5, 2023 and September 20, 2024. prnewswire.com - 1 month ago
8. Profile Summary

Paragon 28, Inc. FNA

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 911 M
Dividend Yield 0.00%
Description Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
Contact 14445 Grasslands Drive, Englewood, CO, 80112 https://www.paragon28.com
IPO Date Oct. 15, 2021
Employees 574
Officers Dr. Matthew Millard Chief Human Resources Officer Mr. Robert S. McCormack J.D. General Counsel & Secretary Mr. John Shumaker Executive Vice President of Sales - U.S. Mr. Hans Kestler Executive Vice President of International Mr. Chadi Chahine Chief Financial Officer & Executive Vice President of Supply Chain Operations Mr. Matthew Brinckman Senior Vice President of Strategy & Investor Relations Mr. Brendan Shook Executive Vice President of Marketing & Medical Education Mr. Albert DaCosta Co-Founder, Chairman, President & Chief Executive Officer Mr. Matthew Jarboe Executive Vice President of Sales & Chief Commercial Officer Mr. Andrew James Hill Executive Vice President of Research & Development